NCT04057898Phase 2, phase 3Active not recruiting

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

Study sponsor: MediciNova

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-04Estimated
Enrollment · participants234Actual
Source updated2026-03-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: Dec 2025. After: Apr 2027.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview